Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by O.O. Oluwole
Outcomes of Patients ≥ 65 Years of Age in Zuma-1, a Pivotal Phase 1/2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Refractory Large B Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Effect of Draw Ratio and Sheet Thickness on Earing and Drawability of Al 1200 Cups
Journal of Minerals and Materials Characterization and Engineering
Related publications
Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients With Refractory Aggressive Non-Hodgkin Lymphoma (NHL): Long-Term Follow-Up of the Pivotal Zuma-1 Trial
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Preliminary Results of Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma
Clinical Cancer Research
Cancer Research
Oncology
Safety and Efficacy of Axicabtagene Ciloleucel (Axi-Cel) in Older Patients: Results From the Us Lymphoma Car-T Consortium
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Safety and Efficacy of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphomas
Therapeutic Advances in Hematology
Hematology
Product Characteristics Associated With in Vivo Expansion of Anti-Cd19 Car T Cells in Patients Treated With Axicabtagene Ciloleucel (Axi-Cel)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Axicabtagene Ciloleucel for CD19+ Plasmablastic Lymphoma
American Journal of Hematology
Hematology
A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase 2 Study of Parsaclisib (Incb050465) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Citadel-202)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
